A PHASE 0/I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF XRD-0394 IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH HIGH GRADE GLIOMAS

Brief description of study

This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gliomas.

Clinical Study Identifier: s24-01715

ClinicalTrials.gov Identifier: NCT06829173

Principal Investigator: Jonathan Tzu-l Yang.

Other Investigators: Caitlin Elizabeth Ordonez Ferri, Douglas S. Kondziolka, Dimitris G Placantonakis, Jessica Goggin, Teresa M Russell, Joshua S. Silverman, Jacqueline Li, Lynda Julie Boulio-Castillo, Benjamin Cooper, Ryan C Mitchell, Marissa Barbaro, Maria Del Pilar Guillermo Prieto Eibl, Jose Ricardo McFaline Figueroa, Jessica D. Schulte, Alexandra Gewirtz, Neil L. Sielski, Cheongeun Oh, Erik P. Sulman, Minerva A Utate, Alexandra M. Miller, Jennifer H Fisher, Daniel A. Orringer, John G Golfinos.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies